Share on StockTwits

Cambrex Corp. (NYSE:CBM) was downgraded by analysts at First Analysis from an “overweight” rating to an “equal weight” rating in a research report issued to clients and investors on Friday, TheFlyOnTheWall.com reports.

In other Cambrex Corp. news, SVP William M. Haskel sold 28,100 shares of the company’s stock on the open market in a transaction dated Thursday, August 7th. The stock was sold at an average price of $22.50, for a total transaction of $632,250.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Cambrex Corp. (NYSE:CBM) traded down 1.72% on Friday, hitting $21.77. 293,627 shares of the company’s stock traded hands. Cambrex Corp. has a 1-year low of $12.56 and a 1-year high of $23.88. The stock has a 50-day moving average of $21.44 and a 200-day moving average of $20.34. The company has a market cap of $667.9 million and a P/E ratio of 20.78.

Cambrex Corp. (NYSE:CBM) last announced its earnings results on Friday, August 1st. The company reported $0.35 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.28 by $0.07. The company had revenue of $98.00 million for the quarter, compared to the consensus estimate of $92.70 million. During the same quarter last year, the company posted $0.10 earnings per share. Cambrex Corp.’s revenue was up 59.2% compared to the same quarter last year. On average, analysts predict that Cambrex Corp. will post $1.11 earnings per share for the current fiscal year.

Separately, analysts at Longbow Research raised their price target on shares of Cambrex Corp. to $27.00 in a research note on Tuesday. They now have a “buy” rating on the stock.

Cambrex Corporation (NYSE:CBM) is a life sciences company, which provides products and services, which accelerate and improve the development and commercialization of new and generic therapeutics.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.